RECORD: Rosiglitazone Evaluated for Cardiovascular Outcomes in oRal agent combination therapy for type 2 Diabetes mellitus

RECORD: Rosiglitazone Evaluated for Cardiovascular Outcomes in oRal agent combination therapy for type 2 Diabetes mellitus

Concerns regarding the cardiovascular safety of thiazolidinediones were reported in earlier studies. RECORD was a study to elucidate the cardiovascular safety of rosiglitazone compared to combination therapy of sulfonylurea + metformin (standard of care)

Thiazolidinediones are associated with an increased risk for heart failure (fluid retention), weight gain, and fractures.

Infographic

Reference

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 Jun 20;373(9681):2125-35.

About the author 

MyEndoConsult

The MyEndoconsult Team. A group of physicians dedicated to endocrinology and internal medicine education.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Pathophysiology Videos


Videos

  • Learn Basic Physiology
  • Pathophysiology (Advanced Concepts)
  • Clinical Correlates
>